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Abstract Capsaicin, a pungent constituent from red chilli
peppers, activates sensory nerve fibres via transient receptor
potential vanilloid receptors type 1 (TRPV1) to release
neuropeptides like calcitonin gene-related peptide (CGRP)
and substance P. Capsaicin-sensitive nerves are widely
distributed in human and porcine vasculature. In this study,
we examined the mechanism of capsaicin-induced relaxa-
tions, with special emphasis on the role of CGRP, using
various pharmacological tools. Segments of human and
porcine proximal and distal coronary arteries, as well as
cranial arteries, were mounted in organ baths. Concentra-
tion response curves to capsaicin were constructed in the
absence or presence of the CGRP receptor antagonist
olcegepant (BIBN4096BS, 1 μM), the neurokinin NK1
receptor antagonist L-733060 (0.5 μM), the voltage-
sensitive calcium channel blocker ruthenium red
(100 μM), the TRPV1 receptor antagonist capsazepine
(5 μM), the nitric oxide synthetase inhibitor N
ω-nitro-L-
arginine methyl ester HCl (L-NAME; 100 μM), the gap
junction blocker 18α-glycyrrhetinic acid (10 μM), as well
as the RhoA kinase inhibitor Y-27632 (1 μM). Further, we
also used the K
+ channel inhibitors 4-aminopyridine
(1 mM), charybdotoxin (0.5 μM)+apamin (0.1 μM) and
iberiotoxin (0.5 μM)+apamin (0.1 μM). The role of the
endothelium was assessed by endothelial denudation in
distal coronary artery segments. In distal coronary artery
segments, we also measured levels of cyclic adenosine
monophosphate (cAMP) after exposure to capsaicin, and in
human segments, we also assessed the amount of CGRP
released in the organ bath fluid after exposure to capsaicin.
Capsaicin evoked concentration-dependent relaxant
responses in precontracted arteries, but none of the above-
mentioned inhibitors did affect these relaxations. There was
no increase in the cAMP levels after exposure to capsaicin,
unlike after (exogenously administered) α-CGRP. Interest-
ingly, there were significant increases in CGRP levels after
exposure to vehicle (ethanol) as well as capsaicin, although
this did not induce relaxant responses. In conclusion, the
capsaicin-induced relaxations of the human and porcine
distal coronary arteries are not mediated by CGRP, NK1,
NO, vanilloid receptors, voltage-sensitive calcium chan-
nels, K
+ channels or cAMP-mediated mechanisms.
Therefore, these relaxant responses to capsaicin are likely
to be attributed to a non-specific, CGRP-independent
mechanism.
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Capsaicin, a pungent constituent of red pepper, is known to
activate sensory C-fibres via transient receptor potential
vanilloid receptors type 1 (TRPV1; Caterina et al. 1997;
Gunthorpe et al. 2002; Szallasi 2006), which are nonselec-
tive cation channels. Activation of these channels increases
influx of mono- and divalent cations, which leads to an
increase in the intracellular Ca
2+ concentrations. Conse-
quently, an array of neuropeptides like calcitonin gene-
related peptide (CGRP), substance P and neurokinin A are
released (Franco-Cereceda et al. 1988; Mitchell et al. 1995).
These neuropeptides play a role in the regulation of normal
vascular smooth muscle tone and are also implicated in
several pathological conditions like ischemic precondition-
ing (Chai et al. 2006), preeclampsia (Dong et al. 2005) and
migraine (Arulmani et al. 2004b). In the pathophysiology of
migraine, vasodilatation of cranial blood vessels, especially
extracerebral intracranial blood vessels, which are richly
innervated by nerves containing a number of peptides such
as CGRP, seems pivotal (Arulmani et al. 2006). Vasodila-
tation of these intracranial arteries leads to activation of
nociceptors, which stimulate the pain centres in the brain
(Goadsby et al. 2002). Involvement of CGRP in the
pathophysiology of migraine is further strengthened by
the observation that olcegepant (BIBN4096BS, Doods et al.
2000), a CGRP receptor antagonist, is effective in the acute
treatment of migraine attacks (Olesen et al. 2004).
Capsaicin has been widely used in various in vivo models
of migraine to induce cranial vasodilatation, which is
attributed to endogenous release of neuropeptides, espe-
cially CGRP (Akerman et al. 2003; Arulmani et al. 2004a;
Gupta et al. 2006a). The involvement of CGRP is further
substantiated in all these in vivo studies by the fact that the
capsaicin-induced vascular responses are all amenable to
blockade with CGRP receptor antagonists. Repeated cap-
saicin challenges are reported to deplete a number of
neurotransmitters, including CGRP in various animal
models (Tang et al. 1997; Tang et al. 1999; Zhou et al.
2002). In addition to the in vivo models, also in vitro
vascular models involving meningeal (Gupta et al. 2006b)
and coronary (Edvinsson et al. 2002; Gupta et al. 2006c)
arteries have been used in migraine research, but vaso-
relaxation in these models was induced by exogenously
administered CGRP. Several major vascular beds, including
the meningeal and coronary (Franco-Cereceda 1988), are
richly innervated with capsaicin-sensitive sensory fibres
containing CGRP (Edvinsson et al. 1987). Meningeal blood
vessels have been shown to be involved in the plasma
protein extravasation in rat dura mater (Delepine and
Aubineau 1997; Seabrook et al. 1996), a model of
neurogenic inflammation, one of the putative mechanisms
in migraine pathophysiology. In this model, capsaicin pre-
treatment has been shown to block plasma protein extra-
vasation, again by depleting neuropeptides (Delepine and
Aubineau 1997). Therefore, it is of interest to investigate
the release of endogenous CGRP in various blood vessels
and capsaicin seems most appropriate for such studies.
Interestingly, very few studies have investigated capsa-
icin-induced relaxations in human isolated blood vessels
(Franco-Cereceda 1991a; Franco-Cereceda et al. 1987).
Based on CGRP-like immunoreactivity, it was claimed that
capsaicin-induced relaxations are mediated by CGRP
(Franco-Cereceda 1991b), but no CGRP receptor antago-
nists were used to unequivocally demonstrate the role of
CGRP in these responses. Therefore, we were interested in
studying capsaicin-mediated relaxations in human and
porcine isolated arteries as a model to study endogenous
release of CGRP in view of its relevance in the pathophys-
iology of migraine. Remarkably, some recent studies
indicate that capsaicin-induced relaxations are mediated
by non-CGRP-mediated mechanisms in guinea pig ileum,
rabbit coronary arteries and equine tracheal smooth muscle
preparations (Fujimoto et al. 2006; Yeon et al. 2001; Zhu et
al. 1997), which is contrary to the observation that
capsaicin-induced relaxations are mediated principally by
CGRP. In these studies, relaxant responses to capsaicin
were mainly attributed to different Ca
2+-activated K
+
channels. Therefore, in the present study, we tried to
characterise capsaicin-induced relaxant response in human
and porcine vessels, with special emphasis on the role of
CGRP, and also investigated other mechanisms, using
different pharmacological tools.
Materials and methods
Tissue preparation
The study protocol was approved by the ethical committee
of Erasmus MC. Human coronary artery was obtained
from ‘heart-beating’ organ donors (13 men, 19 women;
13–65 years) who died due to non-cardiac disorders. The
hearts were provided by the Heart Valve Bank, Rotterdam,
The Netherlands, after donor mediation by Bio Implant
Services Foundation/Eurotransplant Foundation (Leiden,
The Netherlands). The meningeal arteries were obtained
from patients (four men, six women; 41–75 years)
undergoing craniotomy at the neurosurgical unit (n=6) or
from the Department of Pathology (postmortem, n=4)
within 24 h of death, at Erasmus MC, Rotterdam. During
the surgical procedure or autopsy, the dura mater together
with a small piece of the meningeal artery was cut and
placed in a plastic container filled with ice-cold (0–4°C),
physiological salt solution. The artery segment was imme-
diately transported to the laboratory and placed in cold
30 Naunyn-Schmiedeberg’s Arch Pharmacol (2007) 375:29–38oxygenated Krebs bicarbonate solution of the following
composition (mM): NaCl 119, KCl 4.7, CaCl2 1.25,
MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 and glucose 11.1;
pH 7.4. Excess tissue was removed. The meningeal artery
(internal diameter of 350–800 μm) was used the same day
or stored overnight in cold oxygenated modified Krebs
solution and used the following day. Porcine hearts and
heads (pigs of either sex; 6–12 months of age) were
collected from a local slaughterhouse. Porcine basilar
(internal diameter of 150–200 μm) as well as meningeal
(internal diameter of 100–250 μm) arteries were dissected
out from the skull and were placed in a cold oxygenated
Krebs solution as described earlier for human meningeal
arteries. In the laboratory, both human and porcine
proximal (internal diameter, 2–3.5 mm) and distal (internal
diameter, 200–600 μm) coronary arteries were dissected out
of the right ventricle; distal coronary arteries were dissected
with the aid of a microscope and stored in bicarbonate
solution of following composition (mM): NaCl 118, KCl
4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 and
glucose 11.1; pH 7.4.
Functional studies
Both human and porcine proximal coronary artery seg-
ments (3–4 mm length) were suspended with the help of
stainless steel hooks in 15-ml organ baths with a pretension
of 15 mN (optimal tension shown in earlier experiments).
Distal coronary and cranial artery segments were cut into
ring segments of 1–2 mm length and were mounted in
Mulvany myographs between two parallel titanium wires
with a tension normalised to 90% of l100 (distance when
transmural pressure equals 100 mmHg), thus achieving
optimal conditions for active force development (Nyborg et
al. 1987). Vessels were allowed to equilibrate for 30 min in
Krebs solution at 37°C, a similar equilibration period was
repeated after each physical or pharmacological challenge.
In case of human arteries, the cyclo-oxygenase inhibitor
indomethacin (0.1 μM) was added to prevent prostaglandin
synthesis during the whole experimental protocol. Two
successive challenges to KCl (30 mM) were performed to
test the reproducibility of responses. Endothelial integrity
was assessed by observing relaxation to substance P
(10 nM) after precontraction with U46619 (9,11-dideoxy-
11α,9 α-epoxymethano-prostaglandin F2α;1 0n M –1 μM),
followed by washout of the agonists. KCl (18–30 mM,
except where higher concentrations are indicated) or
U46619 (10 nM–1 μM), in case of the K
+ channel blockers,
was used to obtain a stable contraction plateau of around
60–75% of the maximal contraction reached with KCl
(100 mM). Subsequently, capsaicin was added in a
cumulative manner in log steps. The different antagonists
were used to antagonise capsaicin responses, and the
concentration of each of these antagonists was decided on
the basis of highest concentration in the literature unless
mentioned otherwise. Concentration response curves were
constructed in the absence or presence of the CGRP
receptor antagonists olcegepant (1 μM; Gupta et al.
2006b,c) and CGRP8–37 (10 μM; Gupta et al. 2006b,c),
the neurokinin NK1 receptor antagonist L-733060
(0.5 μM; Seabrook et al. 1996), the voltage-sensitive
calcium channel blocker ruthenium red (100 μM, 45–
90 mM KCl was required to get a similar precontraction as
in the corresponding control segments; Franco-Cereceda
and Rudehill 1989), the nitric oxide synthetase inhibitor
N
ω-nitro-L-arginine methyl ester HCl (L-NAME; 100 μM;
Batenburg et al. 2004a,b), as well as the vanilloid receptor
antagonist capsazepine (5 μM; Fujimoto et al. 2006;
Gazzieri et al. 2006). At still higher concentrations of
capsazepine (>5 μM) and L-733006 (>0.5 μM), even
higher concentrations of preconstricting agents could not
produce a workable precontraction.
We also investigated the role of different K
+ channels by
using various inhibitors, 4-aminopyridine (1 mM; Fujimoto
et al. 2006; Yeon et al. 2001), a voltage-dependent K
+
channel (Kv) blocker and charybdotoxin (0.5 μM), a
blocker of Ca
2+-dependent K
+ channels for large conduc-
tance (BKCa) and intermediate conductance (IKCa), in
combination with apamin (0.1 μM), a blocker of small-
conductance Ca
2+-dependent K
+ channels (SKCa; Batenburg
et al. 2004b; Fujimoto et al. 2006; Zhu et al. 1997). The
effect of the RhoA kinase inhibitor, Y-27632 (1 μM;
Fujimoto et al. 2006) was investigated both in the absence
or presence of 4-aminopyridine (1 mM). We also investi-
gated the effect of the gap junction inhibitor 18-α-glycyr-
rhetinic acid (10 μM) on capsaicin-induced relaxations.
Where indicated, the endothelium was removed with a
human hair, and removal was confirmed by observing a
relaxation of less than 10% of precontraction of U46619
after addition of substance P.
Further, in porcine distal coronary artery, we also studied
the effect of repeated administration of capsaicin (50 μM,
four times) to verify the reproducibility of the responses in
view of possible depletion of endogenous peptide pools or
other agents.
Measurements of cAMP
Human proximal and distal, as well as porcine distal,
coronary artery segments were incubated in a medium
containing isobutylmethylxanthine (0.5 mM) for 30 min in
the absence or presence of olcegepant (1 μM). The arterial
segments were exposed to KCl (30 mM), challenged with
ethanol (vehicle of capsaicin, final concentration in the
baths 0.56%), capsaicin (10 μM) or h-αCGRP (100 nM,
serving as a positive control) for 5 min and then snap
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adenosine monophosphate (cAMP) assay. To determine
cAMP, tissues were homogenised in 0.5 ml 0.1 M HCl
using a stainless steel ultraturrax (Polytron, Staufen,
Germany). Homogenates were centrifuged at 3,300×g, and
cAMP was measured in 300 μl supernatant using the
ELISA kit according to the instructions of the manufacturer
(R&D Systems Europe, Abingdom, UK).
Measurements of CGRP in organ bath fluid
Human distal coronary artery segments were subjected to a
similar protocol as during the functional studies, while bath
fluids were collected after construction of the concentration
response curve. The bath fluids were collected from the
segments treated with vehicle and capsaicin (100 μM), and
Krebs solution was used as a control. Bath fluids were
stored in tubes containing aprotinin (0.6 TIU/ml) and stored
at −80°C. A competitive radioimmunoassay (Peninsula Lab
INC., San Carlos, CA, USA) was used according to the
instructions of the manufacturer to measure the CGRP
concentrations in the bath fluid.
Data presentation and statistical analysis
The relaxant responses elicited by the agonists are
expressed as percentage relaxation of the tone induced by
30 mM KCl or U46619 (in case of the K
+ channel
blockers). All data are presented as means±SEM, and n
represents the number of blood vessel segments, all
obtained from different subjects. The effect of all potential
inhibitors of the relaxations to capsaicin was investigated in
a paired parallel setup; that is, relaxations in segments with
inhibitors were always compared to relaxations obtained in
control segments from the same subject. The concentration
response curves for all agonists were analysed using
nonlinear regression analysis, and the potency of agonists
was expressed as pEC50 using Graph Pad Prism 3.01
(Graph Pad Software, San Diego, CA, USA), setting the
Emax of capsaicin in the presence of potential inhibitors to
that in the respective control segment in case it was lower
than the control Emax. The blocking potency of the
antagonists was estimated by calculating median effective
concentration (EC50) ratios, and apparent pKB values were
calculated for the antagonists at each given concentration,
with the slope set to unity. Statistical differences between
concentration response curves to capsaicin in the absence
and presence of potential inhibitors were determined using
Student’sp a i r e dt-test with α set to 1.00–0.95
(1/n) (Motulsky
2003) to correct for multiple comparisons. For the measure-
ments of CGRP in the organ bath fluids, we could not
exclude a non-Gaussian distribution due to the large degree
of variability in the data. Therefore, the levels of CGRP in
bath fluids were analysed by the non-parametric Kruskal–
Wallis test, followed by Dunn’s post hoc multiple compar-
ison test. Significance was assumed at P≤0.05.
Compounds
Human α-CGRP and α-CGRP8–37 were obtained from
Polypeptide, (Wolfenbüttel, Germany), olcegepant
(BIBN4096BS, 1-piperidinecarboxamide, N-[2-[[5-amino-1-
[[4-(4-pyridinyl)-1-piperazinyl]carbonyl] pentyl] amino]-1-
[(3,5-dibromo-4-hydroxyphenyl) methyl]-2-oxoethyl]-4-(1,
4-dihydro-2-oxo-3(2H)-quinazolinyl)-, [R-(R*,S*)]-) was
a gift from Boehringer Ingelheim Pharma (Biberach/Riss,
Germany); 4-aminopyridine was purchased from ICN
Biomedicals (Aurora, OH, USA); L-733060 was pur-
chased from Tocris (Bristol, UK); apamin, capsaicin,
capsazepine, 3-isobutyl-1-methyl-xanthine, L-NAME,
charybdotoxin, ruthenium red, substance P, U46619 and
Y-27632 were purchased from Sigma-Aldrich (Zwijn-
drecht, The Netherlands), and KCl was obtained from
Merck (Darmstadt, Germany). Capsaicin was dissolved in
70% ethanol, and the dilution series was also prepared in
ethanol 70%. Capsazepine was dissolved in methanol;
olcegepant was dissolved in a small amount of 1 N HCl
and then diluted with distilled water. The other com-
pounds were dissolved in distilled water, and all com-
pounds were stored in aliquots at −80°C.
Results
Functional studies
Human arteries
Substance P relaxed artery segments precontracted with
U46619 (10 nM–1 μM); responses were equi-efficacious in
distal coronary (80±5% of contraction to U46619, n=28)
and meningeal (75±8%, n=8) artery and significantly less
in proximal coronary artery (27±15%, n=4). Both in the
meningeal and distal coronary arteries, capsaicin induced
concentration-dependent relaxations. In human proximal
coronary artery, relaxant responses were only observed at
the highest concentration of 100 μM, and the maximum
relaxant response (34±14% of contraction to 30 mM KCl)
was significantly less than that observed in the distal
arteries (94±1% of contraction to 18–30 mM KCl). In
human meningeal arteries, there was no difference in
capsaicin-induced responses between arteries obtained
perioperatively or postmortem; therefore, these data were
pooled for further analysis. Capsaicin was equipotent and
equi-efficacious in human distal coronary and human
meningeal artery. In human distal coronary artery segments,
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some cases induced contractions, but in all cases, we
uniformly only measured the relaxant responses. The
relaxations to capsaicin in proximal and distal coronary as
well as meningeal arterial segments were insensitive to
blockade by the CGRP antagonist olcegepant (1 μM;
Fig. 1, Table 1).
As the relaxant responses to capsaicin were small in
human proximal coronary arteries and the availability of
human meningeal arteries was very limited, further experi-
ments were only carried out in human distal coronary
artery. In this preparation, the CGRP receptor antagonist
CGRP8–37 (10 μM), the TRPV1 receptor antagonist
capsazepine (5 μM) and the NK1 receptor antagonist L-
733006 (0.5 μM) also did not attenuate capsaicin-induced
relaxations (Table 1). Similarly, there was no significant
difference in relaxant responses in endothelium-intact or
endothelium-denuded segments (Table 1). Also, in the
absence or presence of the NO synthase inhibitor L-NAME
(100 μM) or in the presence of the gap junction blocker 18-
α-glycyrrhetinic acid, capsaicin caused equipotent relaxa-
tions compared to the respective control segments (Table 1).
Various K
+ channel blockers, namely, 4-aminopyridine
(1 mM), charybdotoxin (0.5 μM)+apamin (0.1 μM) and
iberiotoxin (0.1 μM)+apamin (0.1 μM) were also unable to
block the relaxant responses to capsaicin. The RhoA kinase
inhibitor Y-27632 (1 μM) alone or in combination with 4-
aminopyridine was also unable to block the relaxant
responses to capsaicin. Ruthenium red (100 μM), a
nonselective blocker of Ca
2+ transport through membrane
channels, also did not significantly block these responses
(Table 1). It is noteworthy that at higher concentrations,
capsazepine and L-733060 significantly attenuated the
responses to their respective preconstriction agents, and
also in case of preincubation with Y-27632 and ruthenium
red, 2- to 20-fold higher concentrations of precontracting
agents were required to induce 60–75% of the maximal
contraction reached with KCl (100 mM). At still higher
concentrations of capsazepine (>5 μM) and L-733060
(>0.5 μM), even higher concentrations of preconstricting
agents could not produce a workable precontraction. Addi-
tionally, the combination of olcegepant (1 μM)+L-733060
(0.5 μM) in human distal coronary artery or 4-amino-
pyridine (1 mM)+Y-27632 (1 μM) both in human and
porcine distal coronary artery were also unable to block the
responses to capsaicin. The vehicle of capsaicin (0.56%
ethanol) did not induce any significant relaxations. It
should be noted that the potency of capsaicin was higher
on a precontraction with U46619 (10 nM–1 μM; pEC50 of
capsaicin, 5.91±0.32) than on a precontraction with KCl
(18–30 mM; pEC50 of capsaicin, 5.27±0.12; P=0.029).
However, irrespective of the precontracting agent used, the
antagonists behaved in a similar fashion towards capsaicin.
For example, the effects of 4-aminopyridine on capsaicin-
induced relaxations were similar after precontraction with
KCl (pEC50, 5.01±0.05 and 5.12±0.41; n=7, in the
absence and presence of 4-aminopyridine, respectively)
and with U46619 (pEC50, 6.58±0.47 and 5.64±0.38; n=6,
in the absence and presence of 4-aminopyridine, respec-
tively). In human meningeal artery, capsazepine, L-733006
and also ruthenium red did not block the responses to
capsaicin (Table 1).
Porcine arteries
In porcine arteries, substance P induced relaxations in
precontracted arteries to a varying degree in different
vessels. The relaxations in distal coronary (64±6% of
contraction to U46619, 10 nM–1 μM, n=26) basilar (44±
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Fig. 1 Effect of capsaicin or its vehicle in the absence or presence of
various pharmacological agents or interventions in precontracted
human and porcine distal coronary arteries
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similar, whereas that in proximal coronary (8±8%, n=4)
artery was significantly smaller. In porcine proximal and
distal coronary arteries, capsaicin induced concentration-
dependent relaxations. Unlike in human coronary arteries,
the maximum response was not significantly different
between porcine proximal and distal coronary arteries
(Table 2). In both the arteries, olcegepant (1 μM) did not
block the responses to capsaicin. Further experiments were
carried out in distal coronary arteries and, similar as in the
human distal coronary artery, capsazepine (1 μM), rutheni-
um red (0.1 mM), L-73360 (0.5 μM), 4-aminopyridine
(1 mM), L-NAME (0.1 mM), charybdotoxin (0.5 μM)+
apamin (0.1 μM), iberiotoxin (0.5 μM)+apamin (0.1 μM),
Y-27632 (1 μM), 18-α-glycyrrhetinic acid (10 μM) and
endothelium denudation did not affect capsaicin-induced
relaxations (Fig. 1, Table 2). Additionally, Y-27632 (1 μM),
alone or combined with 4-aminopyridine (1 mM), was also
unable to block the responses to capsaicin. Similar as in the
other arteries, the vehicle did not induce a relaxation
(Fig. 1). Interestingly, in contrast to what we observed in
the human distal coronary artery, precontracting the arteries
with either KCl or U46619 did not change the relaxant
responses to capsaicin. Four consecutive challenges to
capsaicin (50 μM) did not significantly affect the magni-
tude of the responses (Fig. 2).
There were no significant differences in efficacy or
potency of capsaicin in porcine basilar (Emax, 97±1%;
pEC50, 4.70±0.05; n=3) and meningeal (Emax, 99±1%;
pEC50, 4.82±0.02; n=3) arteries as compared to porcine
distal coronary arteries. In both these arteries, responses to
capsaicin were not affected by olcegepant (1 μM).
Measurements of cAMP
Capsaicin (10 μM) did not affect cAMP levels in
comparison to its vehicle or the control, which was only
exposed to 30 mM KCl. In contrast, αCGRP (100 nM),
which was used as a positive control, significantly
increased cAMP levels in both human and porcine distal
coronary arteries, which was blocked after incubation with
olcegepant (1 μM; Fig. 3).
Table 1 Effect of various antagonists/interventions on capsaicin-induced relaxations in human isolated artery segments
Antagonist or other intervention (n) Emax (%) Δ Emax pEC50 Δ pEC50
Human distal coronary artery
(Control) (32) 94±1 5.27±0.12
Olcegepant (1 μM) (10) 89±4 8±4 4.84±0.09 0.33±0.16
CGRP8–37 (10 μM) (5) 96±3 3±4 4.79±0.06 0.16±0.08
Capsazepine (5 μM) (13) 91±3 1±2 5.10±0.13 0.07±0.16
Ruthenium red (0.1 mM) (9) 92±3 5±3 5.01±0.13 0.21±0.22
L-733060 (5 μM) (7) 94±2 2±2 6.03±0.78 −0.54±0.34
Denuded endothelium (5) 90±6 9±5 5.34±0.48 −0.21±0.58
L-NAME (0.1 mM) (7) 94±2 3±2 5.23±0.48 −0.24±0.45
18-α-Glycyrrhetinic acid (10 μM) (3) 96±2 0±2 5.08±0.28 −0.15±0.38
Olcegepant (1 μM)+L-733060 (5 μM) (3) 90±6 1±3 6.04±0.23 0.06±0.21
(Control) (10) 97±1 5.91±0.32
4-Aminopyridine (1 mM) (6) 95±2 2±3 5.64±0.38 0.94±0.46
Charybdotoxin (0.5 μM)+apamin (0.1 μM) (8) 97±1 0±1 5.80±0.37 0.23±0.37
Iberiotoxin (0.5 μM)+apamin (0.1 μM) (5) 96±2 0±2 5.94±0.65 0.15±0.38
Y-276323 (1 μM) (3) 99±1 −1±2 5.39±0.21 −0.58±0.14
Y-276323 (1 μM)+4-Aminopyridine (1 mM) (3) 100±0 −3±4 5.12±0.18 0.33±0.28
Human proximal coronary artery
(Control) (4) 34±14 4.30±0.14
Olcegepant (1 μM) (4) 36±16 4.40±0.17
Human meningeal artery
(Control) (10) 91±5 5.04±0.09
Olcegepant (1 μM) (10) 96±1 −5±4 5.03±0.07 −0.07±0.08
Capsazepine (5 μM) (4) 81±9 8±7 4.90±0.31 0.11±0.31
Ruthenium red (0.1 mM) (3) 74±15 5±14 5.13±0.42 0.02±0.62
L-733060 (5 μM) (4) 79±12 8±15 4.80±0.31 −0.09±0.31
Emax is the maximum relaxant response, expressed as percentage of the respective precontraction; pEC50 is the −logEC50, where EC50 is the
concentration of agonist required to produce half the maximal response. The arteries were precontracted with KCl (18–30 mM) except where
KCl (45–90 mM; bold) or U46619 (ital).
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Capsaicin and its vehicle induced a significant CGRP
release from human distal coronary artery segments into the
organ bath fluid (Fig. 4) as compared to levels observed in
Krebs solution. There was no significant difference between
CGRP levels obtained after incubation with capsaicin or its
vehicle.
Discussion
In the present study, we investigated the role of CGRP in
capsaicin-induced relaxations in human and porcine isolat-
ed arteries. In all arteries investigated, there does not seem
to be any relevant role of CGRP in the relaxant responses to
capsaicin. Further, the effects of capsaicin appear to be
mediated by non-specific mechanisms.
In all arteries investigated, capsaicin induced concentra-
tion-dependent relaxations, although these had a limited
potency and efficacy in human proximal coronary artery.
The responses to capsaicin were resistant to blockade with
olcegepant in all tissues studied, which suggests no
involvement of CGRP receptors. The potency of capsaicin
is in line with what has earlier been observed in human
coronary arteries (Franco-Cereceda 1991a) and guinea pig
ileum (Fujimoto et al. 2006). As expected in view of its
Table 2 Effect of various antagonists/interventions on capsaicin-induced relaxations in porcine isolated artery segments
Antagonist or other intervention (n) Emax (%) Δ Emax pEC50 Δ pEC50
Porcine distal coronary artery
(Control) (56) 96±1 5.27±0.09
Olcegepant (1 μM) (10) 92±2 3±2 5.26±0.11 −0.02±0.11
CGRP8–37 (10 μM) (5) 97±3 −2±5 4.78±0.06 0.00±0.03
Capsazepine (5 μM) (7) 99±1 −3±2 5.15±0.26 0.26±0.16
Ruthenium red (0.1 mm) (12) 88±3 7±4 4.89±0.09 0.47±0.23
L-733060 (5 μM) (7) 88±3 4±4 4.89±0.09 −0.04±0.15
Denuded endothelium (9) 91±4 2±2 5.62±0.49 0.21±0.16
L-NAME (0.1 mM) (6) 90±8 8±8 4.84±0.15 0.28±0.31
(Control) (15) 99±0 5.08±0.15
18-α-Glycyrrhetinic acid (10 μM) (3) 99±1 0±1 5.73±0.75 −0.59±0.53
4-Aminopyridine (1 mM) (7) 96±2 3±2 4.84±0.15 −0.46±0.35
Charybdotoxin (0.5 μM)+apamin (0.1 μM) (11) 99±1 0±1 5.27±0.15 −0.04±0.20
Y-276323 (1 μM) (9) 96±2 3±2 5.17±0.19 0.04±0.21
Y-276323 (1 μM)+4-Aminopyridine (1 mM) (8) 96±3 4±3 5.22±0.20 0.00±0.11
Porcine proximal coronary artery
(Control) (4) 100±0 5.33±0.42
Olcegepant (1 μM) (4) 90±6 5.79±0.16
Porcine basilar artery
(Control) (3) 97±1 4.70±0.05
Olcegepant (1 μM) (3) 100±0 4.97±0.24
Capsazepine (5 μM) (3) 100±0 4.80±0.01
Porcine meningeal artery
(Control) (3) 99±1 4.82±0.02
Olcegepant 1 μM (3) 99±1 4.88±0.04
Emax is the maximum relaxant response, expressed as percentage of the respective precontraction; pEC50 is the −logEC50, where EC50 is the
concentration of agonist required to produce half the maximal response. The arteries were precontracted with KCl (18–30 mM) except where
KCl (45–90 mM; bold) or U46619 (ital).
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Fig. 2 Effect of four consecutive challenges to capsaicin (50 μM) in
porcine distal coronary arteries precontracted with KCl (30 mM)
Naunyn-Schmiedeberg’s Arch Pharmacol (2007) 375:29–38 35resistance to olcegepant, CGRP8–37 (10 μM) also did not
block capsaicin-induced relaxations in human distal coro-
nary artery segments. This is contrary to the observations
by Franco-Cereceda and Rudehill (1989), where the authors
claim the relaxations to capsaicin are mediated by CGRP on
the basis of the observation that the sustained relaxations in
the human coronary induced by capsaicin are similar to
those induced by exogenous CGRP, unlike the transient
relaxations to substance P, which are followed by rapid
tachyphylaxis. In another publication, these authors claim
involvement of CGRP in responses to capsaicin in the
human isolated coronary artery on the basis of increased
CGRP-like immunoreactivity after exposure of the artery
segments to capsaicin (Franco-Cereceda 1991b). It should
be noted that in the above study, the authors show an
increase in CGRP-like immunoreactivity in large arteries,
where no functional studies were performed. Further, the
classical prerequisite for demonstrating the involvement of
a particular pharmacological agent, by using the
corresponding antagonist to block functional responses,
was lacking in this study. Admittedly, the same group did
demonstrate that CGRP8–37 inhibited the responses to
capsaicin in porcine coronary arteries (Franco-Cereceda
1991b), although we could not block these responses even
at 10-μM concentration.
As CGRP-induced responses are mediated by increases
in cAMP (Gupta et al. 2006c), we measured the levels of
this second messenger after exposure to capsaicin and
CGRP. We observed no increase in cAMP after addition of
capsaicin, in contrast to the increased levels of cAMP after
exposure of the vessel segments to (exogenous) α-CGRP.
These increased levels were, as expected, blocked by the
CGRP receptor antagonist olcegepant. Interestingly, after
exposure to capsaicin, we observed CGRP release in the
organ bath fluid, where the human distal coronary arteries
were mounted in accordance with earlier observations
(Franco-Cereceda 1991a). However, a similar increase was
observed after administration of vehicle, while the control
was not studied in the study of Franco-Cereceda et al.
(1991a). Although capsaicin is known to activate TRPV1,
there are reports that ethanol, also via activation of TRPV1,
induces the release of CGRP as well (Trevisani et al. 2002,
2004). Moreover, as obvious from Fig. 1, the vehicle did
not induce any relaxations in the precontracted arteries, and
hence, the released CGRP cannot account for relaxations
induced by capsaicin. Interestingly, the concentration of
CGRP detected in the bath fluid of about 3 pM should have
been about 10,000 times higher in the vessel segments
(∼0.5 mg tissue in 5-ml organ bath fluid). Thus, the
concentration of CGRP in the vessel segments should have
been in the nanomolar range, which is equal to or even
higher than the pEC50 in human distal coronary artery
under similar experimental conditions (Gupta et al. 2006c)
and should, thus, have induced a detectable relaxation.
Therefore, it is most likely that the radioimmunoassay
displayed cross-reactivity to another ligand, not CGRP.
Admittedly, our observation that ruthenium red, even at a
Fig. 4 CGRP levels measured in bath fluids (Krebs buffer, control)
after capsaicin or vehicle challenge in precontracted human distal
coronary artery segments. *Significantly different (P<0.05) from
Krebs buffer
Fig. 3 Changes in cAMP levels in human (n=4–7) and porcine (n=
4–9) distal coronary artery segments after exposure to various
pharmacological agents. *Significantly different (P<0.05) from KCl
(30 mM)-treated segments
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responses to capsaicin, is in contrast with the observations
described by Franco-Cereceda (1991a), where ruthenium
red completely blocked the responses to capsaicin. Addi-
tional evidence for the fact that CGRP and TRPV1 are not
involved in relaxant responses to capsaicin is provided by
the fact that capsazepine, a competitive antagonist of
TRPV1 (Caterina et al. 1997), did not block responses to
capsaicin in our study.
In view of reports of involvement of various K
+ channels
in the relaxant responses to capsaicin in various smooth
muscle preparations (Yeon et al. 2001; Zhu et al. 1997), we
also investigated various K
+ channel inhibitors in similar or
even higher concentrations, but none of these blocked the
responses to capsaicin. 4-Aminopyridine, a blocker of
delayed rectifier K
+ channels, which is reported to block
the responses to capsaicin in rabbit coronary artery (Yeon et
al. 2001) and guinea pig ileum (Fujimoto et al. 2006), was
ineffective in human as well as porcine distal coronary
artery. Similarly, charybdotoxin, a BKCa and IKCa blocker,
which blocked capsaicin responses in equine tracheal
smooth muscle (Zhu et al. 1997), did not block these
responses at similar concentrations and even in combination
with apamin, a SKCa blocker. We also used the RhoA
kinase inhibitor Y-27632, but unlike in guinea pig ileum,
(Fujimoto et al. 2006) it also did not antagonise responses
to capsaicin in the isolated preparations used in the present
study. The capsaicin-mediated responses appear to be
endothelium-independent, as denudation of the endotheli-
um did not significantly change the capsaicin-induced
responses. Further, the vehicle of capsaicin was without
effect and, hence, cannot account for the relaxant responses
to capsaicin. Moreover, repeated administration of capsai-
cin in porcine coronary artery did not significantly decrease
the responses, suggesting that stored neuropeptides are not
responsible for the relaxations, as these would most likely
be depleted after repeated challenges to capsaicin (Sams-
Nielsen et al. 2001). Unlike in the present study, relaxations
in precontracted guinea pig isolated pulmonary artery could
not be repeated with capsaicin indicating depletion of
neurotransmitters (Maggi et al. 1990). Although we did not
include a positive control for the various K
+ blockers in the
current study, in the same set up at our laboratory, relaxant
responses to L-S-nitrosocysteine were blocked by the
combination of charybdotoxin (100 nM) and apamin
(100 nM) in porcine distal arteries (Batenburg et al.
2004b). Further, the concentrations of the various inhibitors
that we used in our study were equal to (Yeon et al. 2001;
Zhu et al. 1997) or even higher (Yeon et al. 2001) than
those employed by others.
Taken together, our observations in human and porcine
distal coronary artery suggest that capsaicin-induced
responses are not mediated by CGRP, substance P or
TRPV1 receptors and also do not involve various Ca
2+-
activated K
+ channels. The relaxations to capsaicin are
mediated by a cAMP independent pathway. The major
component of capsaicin-induced relaxations, therefore,
appears to be mediated by non-specific actions of capsaicin,
rather than from the release of neuropeptides like CGRP.
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